Lexaria Bioscience Corp.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US52886N4060
USD
0.73
0.02 (2.34%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Cyclerion Therapeutics, Inc.
Sunshine Biopharma, Inc.
Blue Water Biotech, Inc.
Talphera, Inc.
Neurosense Therapeutics Ltd.
Lexaria Bioscience Corp.
Theriva Biologics, Inc.
Shuttle Pharmaceuticals Holdings, Inc.
Trevena, Inc.
Timber Pharmaceuticals, Inc.
Comera Life Sciences Holdings, Inc.

Why is Lexaria Bioscience Corp. ?

Icon
Unrated Stock - No Analysis Available
stock-recommendationReal-Time Research Report

Verdict Report

Icon
No Data Found

Is Lexaria Bioscience Corp. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Lexaria Bioscience Corp.
-58.76%
-0.79
99.29%
S&P 500
16.12%
0.77
19.29%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
2.66%
EBIT Growth (5y)
-190.44%
EBIT to Interest (avg)
-6.91
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.83
Sales to Capital Employed (avg)
0.09
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
17.63%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.58
EV to EBIT
-1.25
EV to EBITDA
-1.26
EV to Capital Employed
13.22
EV to Sales
13.22
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1054.98%
ROE (Latest)
-214.71%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

11What is working for the Company
DEBT-EQUITY RATIO (HY)

Lowest at -87.98 %

DEBTORS TURNOVER RATIO(HY)

Highest at 2.97 times

OPERATING PROFIT(Q)

Highest at USD -1.55 MM

PRE-TAX PROFIT(Q)

Highest at USD -1.57 MM

NET PROFIT(Q)

Highest at USD -1.57 MM

EPS(Q)

Highest at USD -0.07

-7What is not working for the Company
NET SALES(HY)

At USD 0.17 MM has Grown at -35.06%

ROCE(HY)

Lowest at -146.97%

RAW MATERIAL COST(Y)

Grown by 101.26% (YoY

Here's what is working for Lexaria Bioscience Corp.

Operating Profit
Highest at USD -1.55 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (USD MM)

Pre-Tax Profit
Highest at USD -1.57 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Pre-Tax Profit
At USD -1.57 MM has Grown at 46.03%
over average net sales of the previous four periods of USD -2.92 MM
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit
Highest at USD -1.57 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (USD MM)

Net Profit
At USD -1.57 MM has Grown at 46.01%
over average net sales of the previous four periods of USD -2.91 MM
MOJO Watch
Near term Net Profit trend is positive

Net Profit (USD MM)

EPS
Highest at USD -0.07
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Debt-Equity Ratio
Lowest at -87.98 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Debtors Turnover Ratio
Highest at 2.97 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Here's what is not working for Lexaria Bioscience Corp.

Net Sales
At USD 0.17 MM has Grown at -35.06%
Year on Year (YoY)
MOJO Watch
Near term sales trend is very negative

Net Sales (USD MM)

Raw Material Cost
Grown by 101.26% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales